Item 8.01. Other Events

On November 29, 2021, Dyadic International, Inc. ("Dyadic" or the "Company") posted a presentation entitled "C1 Technology Platform: Rapid response to Pandemic and other biological threats - Support the global combat against SARS-CoV-2 Variants of Concern" on the Company's website at www.dyadic.com under the "Investors" tab.

The presentation highlights certain data, including a successful completion of a toxicology study, which further supports the platform's flexible production capabilities allowing for highly scalable antigen production with the ability to rapidly address emerging infectious diseases, including COVID-19 variants of concern.

Dyadic's C1 technology has demonstrated the ability to rapidly develop Alpha, Beta, Gamma and Delta antigens alone or in various combinations from a single C1-cell line, which has broad global implications, for countries who currently lack an efficient vaccine manufacturing and distribution infrastructure. The presentation also discusses the initiation of development of a COVID-19 antigen against the emerging Omicron variant of concern.

Representatives of Dyadic will use the presentation in industry conferences, investor conferences and investor meetings from time to time. A copy of the presentation is also attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.




Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is being furnished herein:
      Exhibit
      Number          Description

       99.1             Dyadic International Presentation, "C1 Technology
                      Platform: Rapid response to Pandemic and other biological
                      threats - Support the global combat against SARS-CoV-2
                      Variants of Concern", dated November 29, 2021
        104           Cover page Interactive Data File (embedded within the Inline
                      XBRL document)

© Edgar Online, source Glimpses